Novel immunotherapy vaccine decreases recurrence in HER2 positive breast cancer patients
A new breast cancer vaccine candidate, (GP2), provides further evidence of the potential of immunotherapy in preventing disease recurrence. One of only a few vaccines of its kind in development, GP2 has been shown to be safe and effective for breast cancer patients, reducing recurrence rates by 57%. Further, women with the highest overexpression of HER2 (known as HER2 +3) had no cancer recurrences when they were administered the vaccine after completing trastuzumab (Herceptin), a type of immunotherapy drug known as a monoclonal antibody.
Source: ScienceDaily Headlines - Category: Science Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | Cancer Vaccines | HER2 | Herceptin | Immunotherapy | Science | Vaccines | Women